Treatment of aregeneratoric anemia following an ABO-incompatible allogeneic peripheral blood stem cell transplantation: A case report
Therapeutic Apheresis, cilt.3, sa.3, ss.275-277, 1999 (Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 3 Sayı: 3
- Basım Tarihi: 1999
- Doi Numarası: 10.1046/j.1526-0968.1999.00135.x
- Dergi Adı: Therapeutic Apheresis
- Derginin Tarandığı İndeksler: Scopus
- Sayfa Sayıları: ss.275-277
- Anahtar Kelimeler: ABO mismatch, Allogeneic peripheral blood stem cell transplantation, Aregeneratoric anemia
- Lokman Hekim Üniversitesi Adresli: Evet
Özet
Aregeneratoric anemia (AA) occurs rarely after ABO-incompatible allogeneic peripheral blood stem cell transplantation (alloPBSCT), and its management is generally difficult. Here, we present a 31-year-old white man with myelodysplastic syndrome who developed AA after receiving stem cells from his human leukocyte antigen (HLA) identical, but ABO-incompatible sibling. Because his anti-A antibody titers were high, therapy with conventional doses of erythropoietin and prednisolone failed to treat the AA. Following 8 cycles of plasma exchange and higher doses of erythropoietin and prednisolone as well as danazol administration, anti-A titers decreased, and his anemia improved significantly. In conclusion, to treat and obtain a low titer of antibodies in a patient with AA following an ABO-incompatible alloPBSCT, higher doses of erythropoietin and corticosteroids associated with plasma exchange have to be used.